Lv7
4988 积分 2022-08-01 加入
Antibody–Drug Conjugates in Small-Cell Lung Cancer: DLL3, B7-H3, TROP2 and Beyond
10天前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
14天前
已完结
Remarkable response after cocktail therapy with 177Lu-PSMA and 177Lu-DOTA-IBA in the treatment of mCRPC
1个月前
已完结
[ 177 Lu]Lu-DOTATATE and [ 177 Lu]Lu-DOTA-IBA Cocktail Therapy for Metastatic Small Cell Lung Cancer: Possible Applications in Clinical Practice
1个月前
已完结
ADC for SCLC Clears Phase I
1个月前
已完结
SGO 2026 title page的pdf文件
1个月前
已完结
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
1个月前
已完结
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
2个月前
已完结
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial
2个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308